1
|
Gaillard S, Broadwater G, Andrews W, Starr M, Previs R, Havrilesky L, Davidson B, Berchuck A, Yi J, Nixon A, Secord A. Pembrolizumab window study: Illuminating the immunologic landscape in gynecologic cancers. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.06.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
2
|
Chino F, Castellar E, Schild M, Blitzblau R, Georgiade G, Suneja G, Duffy E, Broadwater G, Horton J. Pathologic Response and Acute Toxicity: Planned Interim Analysis of the Phase 2 NeoRT Trial Evaluating Preoperative Single Fraction Partial Breast Radiation Therapy in Early Stage Breast Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Kelsey C, Beaven A, Diehl L, Broadwater G, Prosnitz L. Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
4
|
Carpenter D, Broadwater G, Mowery Y, Rodrigues A, Wisdom A, Clough R, Brizel D. The Incidence of Carotid Stenosis in Head and Neck Cancer Patients After Radiation Therapy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
5
|
Foote J, Gaillard S, Broadwater G, Sosa J, Chino J, Havrilesky L. Optimal surgical and adjuvant treatment modalities in vulvar melanoma: An analysis of 1,780 cases of vulvar melanoma in the National Cancer Data Base. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
6
|
Force J, Abbott S, Broadwater G, Kimmick G, Westbrook K, Hwang S, Kauff N, Stashko I, Weinhold K, Nair S, Hyslop T, Blackwell K, Castellar E, Marcom PK. Abstract P2-04-19: Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-04-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Increased stromal tumor infiltrating lymphocytes (TILs) are predictive and prognostic for improved outcomes from neoadjuvant or adjuvant chemotherapy in triple negative breast cancer. Increased tumor mutational burden may promote neoantigens causing immune system upregulation. Microsatellite instability in gastrointestinal cancer predicts for response to checkpoint inhibition and is associated with inherited cancer predisposition. The immune system response in BRCA mutated breast cancer has not been described. The purpose of this study is to assess tumor infiltrating immune cells in early stage breast cancer patients with and without BRCA gene mutations.
Methods: We retrospectively investigated 124 early stage breast cancer patients with BRCA mutations (n=62, BRCA+) and without BRCA mutations (n=62, BRCA WT). The %TILs was measured manually by H&E. Our control group consisted of age, stage, and receptor status matched early stage untreated breast cancer patients who were deemed BRCA WT by extended gene panel testing or were negative for BRCA 1/2 and had a posttest probability of harboring an autosomal dominant mutated gene of ≤ 1% using the Bayes-Mendel algorithm. We used a two-sample binomial arcsin approximation to detect a 20% difference in TILs between cohorts to attain 80% power with a one-side alpha of 0.05. Wilcoxon Rank-Sums test was used to compare differences in the central tendencies for continuous variables. We used the Nanostring PanCancer immune profiling panel to immunophenotype a portion of the BRCA+ and BRCA WT cohorts and used nSolver for quality control, normalization, and bioinformatics analyses.
Results: Here we report TILs from the first 21 patients of our study. Thirteen patients harbored BRCA mutations and eight patients did not. All patients were HER2 negative. Eight (61%) and four (50%) patients were hormone receptor positive (HR+) in the BRCA+ and BRCA WT cohorts, respectively. Median %TILs were not significantly different between the BRCA+ (15, range 0-70) and BRCA WT (17.5, range 5-60; p=0.7) groups. Median %TILs in the HR+/BRCA+ (12.5, range 0-50) and HR-/BRCA+ (15, range 5-70) cohorts were not statistically different when compared to HR+/BRCA WT (10, range 5-15; p=0.4) and HR-/BRCA WT (30, range 20-60; p=0.2) cohorts, respectively. There were 2 patients with lymphocyte predominant breast cancer (n=1, HR-/BRCA+; n=1, HR-/BRCA WT).
Conclusions: This is the first study to characterize TILs and a tumor immune microenvironment phenotype in early stage breast cancer patients with BRCA mutations. These results suggest harboring a BRCA mutation is not associated with increased TILs in early stage untreated breast cancer patients. This conclusion stayed true regardless of hormone receptor status. However, a trend of decreased TILs was seen in HR-/BRCA+ patients when compared to those with HR-/BRCA WT disease. Moreover, the median and range of TILs were higher in the HR+/BRCA+ group compared to the HR+/BRCA WT group. This suggests increased TILs may exist in some HR+ patients with a BRCA mutation. Further investigation of TILs and immune profiling of early stage untreated breast cancer patients with and without BRCA mutations is warranted.
Citation Format: Force J, Abbott S, Broadwater G, Kimmick G, Westbrook K, Hwang S, Kauff N, Stashko I, Weinhold K, Nair S, Hyslop T, Blackwell K, Castellar E, Marcom PK. Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-04-19.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - S Nair
- Duke University, Durham, NC
| | | | | | | | | |
Collapse
|
7
|
Narloch JL, Harnden K, Broadwater G, Peterson B, Hyslop T, Kirkpatrick J, Fecci P, Kim G, Blackwell KL. Abstract P5-08-12: HER2 status remains the primary predictor of improved survival in patients with BCBM over the past 2 decades (1996-2015). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-08-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Brain metastasis is a complication in advanced breast cancer (ABC) and is associated with poor prognosis. Incidence of breast cancer brain metastasis (BCBM) is increasing with advances in therapy, allowing patients to survive long enough to develop CNS metastasis. Improved outcomes have been documented in ABC over the past decades, largely related to the use of trastuzumab in HER2+ ABC. However, it remains unclear whether survival has improved in HER2- ABC in patients with BCBM. This study asks: has the improvement in systemic and radiotherapies for HER2- breast cancer impacted survival in patients with breast cancer brain metastasis.
OBJECTIVES: 1) To estimate whether date of BCBM diagnosis is associated with overall survival (OS) in patients diagnosed between 1996-2015. 2) To estimate whether OS of this patient population depends upon other demographic and clinical factors.
METHODS: This is a retrospective chart review of patients with diagnosis of BCBM between 1996-2015. Data collection includes: age at BCBM diagnosis, ethnicity, ER/PR/HER2 status, date of BCBM diagnosis, date of primary breast cancer diagnosis, date of death/last clinical follow-up, and treatment. Kaplan-Meier analysis and the log-rank test compared OS (time from diagnosis of BCBM until death or last clinical FU) between groups diagnosed in 5-year cohorts (1996-2000, 2001-2005, 2006-2010, 2011-2015). A univariate proportional hazards model was used to regress OS on date of diagnosis. A multivariate proportional hazards model was used which included the subset of patients diagnosed with BCBM in 2001 and later. This model adjusted for additional factors: race, time to development of BCBM diagnosis, age at the time of BCBM diagnosis, year of diagnosis as a continuous factor, ER, PR, while testing the significance of HER2 status. A p-value < 0.05 was significant.
RESULTS: A total of 165 patients with BCBM were included in this analysis, with a median age of 53.8 (SD 13.0) at time of BCBM diagnosis. Most patients were Caucasian (66%; 109/165) or African-American (29%; 48/165). Although statistical significance was not attained, greater median overall survival was seen for patients diagnosed with BCBM in more recent 5-year cohorts (2011-2016, 9.5 months; 2006-2010, 8 months) than patients in older cohorts (2001-2006, 3.6 months; 1996-2000, 5.3 months), p=0.3. Date of diagnosis of BCBM as a continuous variable is predictive of overall survival (HR 0.83 [95% CI: 0.71-0.97] comparing 5-year intervals, p=0.016). After adjusting for the covariates listed above, HER2 positive status is predictive of overall survival (HR 0.34 [95% CI: 0.34-0.56]; p<0.0001).
CONCLUSIONS: While survival has improved by 5.9 months over the past two decades, it remains highly dependent on HER2 status. Novel therapies for BCBM are greatly needed for ER+ and triple negative subtypes. Final results will include an expanded analysis to incorporate additional cases and three other categorical covariates measured during follow-up: whether the patient received radiotherapy, surgery, and/or medical therapy after diagnosis of brain metastases.
GRANT FUNDING: TL-1 CTSA Pre-Doctoral Training Grant (5TL1TR001116-03).
Citation Format: Narloch JL, Harnden K, Broadwater G, Peterson B, Hyslop T, Kirkpatrick J, Fecci P, Kim G, Blackwell KL. HER2 status remains the primary predictor of improved survival in patients with BCBM over the past 2 decades (1996-2015) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-12.
Collapse
Affiliation(s)
- JL Narloch
- Clinical Research Training Program, Duke University Medical Center, Durham, NC; Duke University Medical Center, Durham, NC; Duke Cancer Institute, Durham, NC
| | - K Harnden
- Clinical Research Training Program, Duke University Medical Center, Durham, NC; Duke University Medical Center, Durham, NC; Duke Cancer Institute, Durham, NC
| | - G Broadwater
- Clinical Research Training Program, Duke University Medical Center, Durham, NC; Duke University Medical Center, Durham, NC; Duke Cancer Institute, Durham, NC
| | - B Peterson
- Clinical Research Training Program, Duke University Medical Center, Durham, NC; Duke University Medical Center, Durham, NC; Duke Cancer Institute, Durham, NC
| | - T Hyslop
- Clinical Research Training Program, Duke University Medical Center, Durham, NC; Duke University Medical Center, Durham, NC; Duke Cancer Institute, Durham, NC
| | - J Kirkpatrick
- Clinical Research Training Program, Duke University Medical Center, Durham, NC; Duke University Medical Center, Durham, NC; Duke Cancer Institute, Durham, NC
| | - P Fecci
- Clinical Research Training Program, Duke University Medical Center, Durham, NC; Duke University Medical Center, Durham, NC; Duke Cancer Institute, Durham, NC
| | - G Kim
- Clinical Research Training Program, Duke University Medical Center, Durham, NC; Duke University Medical Center, Durham, NC; Duke Cancer Institute, Durham, NC
| | - KL Blackwell
- Clinical Research Training Program, Duke University Medical Center, Durham, NC; Duke University Medical Center, Durham, NC; Duke Cancer Institute, Durham, NC
| |
Collapse
|
8
|
Chino J, Foote J, Broadwater G, Secord A, Jones M, Havrilesky L, Gaillard S. National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence. Gynecol Oncol 2016. [DOI: 10.1016/j.ygyno.2016.04.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Gaillard S, Broadwater G, Foote J, Adam M, Secord A, Jones M, Sosa J, Havrilesky L, Chino J. Outcomes and national practice patterns in management of ovarian carcinosarcoma compared with high-grade papillary serous ovarian carcinoma: An NCDB analysis of 76,369 patients. Gynecol Oncol 2016. [DOI: 10.1016/j.ygyno.2016.04.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Blitzblau R, Wright A, Arya R, Broadwater G, Pura J, Hardenbergh P, Borges-Neto S, Wong T, Marks L, Horton J. Are Long-term Cardiac Outcomes Predicted by Short-term Postradiation Cardiac Perfusion Deficits: An 8–15 Year Follow-up of a Prospective Study. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.256] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
11
|
Cobb L, Whitaker R, Hall A, Broadwater G, Murphy S, Berchuck A, Gaillard S. Evaluation of ERRα expression and association with survival in advanced ovarian cancer. Gynecol Oncol 2015. [DOI: 10.1016/j.ygyno.2015.01.513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Davidson B, Mannschreck D, Broadwater G, Lopez-Acevedo M, Lee P, Havrilesky L, Valea F, Berchuck A, Secord A. Findings at laparoscopy, not debulking status, are associated with survival in advanced stage ovarian cancer after neoadjuvant chemotherapy. Gynecol Oncol 2015. [DOI: 10.1016/j.ygyno.2015.01.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
13
|
Glass OK, Inman BA, Broadwater G, Courneya KS, Mackey JR, Goruk S, Nelson ER, Jasper J, Field CJ, Bain JR, Muehlbauer M, Stevens RD, Hirschey MD, Jones LW. Effect of aerobic training on the host systemic milieu in patients with solid tumours: an exploratory correlative study. Br J Cancer 2015; 112:825-31. [PMID: 25584487 PMCID: PMC4453949 DOI: 10.1038/bjc.2014.662] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Revised: 12/01/2014] [Accepted: 12/17/2014] [Indexed: 12/18/2022] Open
Abstract
Background: Few studies have investigated the effects of exercise on modulation of host factors in cancer patients. We investigated the efficacy of chronic aerobic training on multiple host-related effector pathways in patients with solid tumours. Patients and Methods: Paired peripheral blood samples were obtained from 44 patients with solid tumours receiving cytotoxic therapy and synthetic erythropoietin (usual care; n=21) or usual care plus supervised aerobic training (n=23) for 12 weeks. Samples were characterised for changes in immune, cytokine and angiogenic factors, and metabolic intermediates. Aerobic training consisted of three supervised cycle ergometry sessions per week at 60% to 100% of peak oxygen consumption (VO2peak), 30–45 min per session, for 12 weeks following a nonlinear prescription. Results: The between-group delta change in cardiopulmonary function was +4.1 ml kg −1 min−1, favouring aerobic training (P<0.05). Significant pre–post between-group differences for five cytokine and angiogenic factors (HGF, IL-4, macrophage inflammatory protein-1β (MIP-1β), vascular endothelial growth factor (VEGF), and TNF-α) also favour the aerobic training group (P's<0.05). These reductions occurred in conjunction with nonsignificant group differences for T lymphocytes CD4+, CD8+, and CD8+/CD45RA (P<0.10). For these factors, circulating concentrations generally increased from baseline to week 12 in the aerobic training group compared with decreases or no change in the usual care group. No significant changes in any metabolic intermediates were observed. Conclusions: Aerobic training alters host availability of select immune–inflammatory effectors in patients with solid tumours; larger confirmatory studies in more homogenous samples are warranted.
Collapse
Affiliation(s)
- O K Glass
- Duke University Medical Center, Durham, NC, USA
| | - B A Inman
- Duke University Medical Center, Durham, NC, USA
| | | | - K S Courneya
- University of Alberta, Edmonton, Alberta, Canada
| | - J R Mackey
- University of Alberta, Edmonton, Alberta, Canada
| | - S Goruk
- University of Alberta, Edmonton, Alberta, Canada
| | - E R Nelson
- Duke University Medical Center, Durham, NC, USA
| | - J Jasper
- Duke University Medical Center, Durham, NC, USA
| | - C J Field
- University of Alberta, Edmonton, Alberta, Canada
| | - J R Bain
- Duke University Medical Center, Durham, NC, USA
| | | | - R D Stevens
- Duke University Medical Center, Durham, NC, USA
| | | | - L W Jones
- Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
| |
Collapse
|
14
|
Turner T, Habib A, Broadwater G, Valea F, Fleming N, Havrilesky L. Postoperative pain scores and narcotic use in robotic-assisted versus laparoscopic hysterectomy for endometrial cancer. Gynecol Oncol 2014. [DOI: 10.1016/j.ygyno.2014.03.517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Horton JK, Blitzblau RC, Yoo S, Georgiade GS, Geradts J, Baker JA, Chang Z, Broadwater G, Barry W, Duffy EA, Hwang ES. Abstract P5-14-04: Preoperative single-fraction partial breast radiotherapy – Initial results from a novel phase I dose-escalation protocol with exploration of radiation response biomarkers. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-14-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose/Objectives(s): Women with biologically favorable early stage breast cancer are increasingly treated with accelerated partial breast techniques. However, many alternative techniques require costly specialized equipment not routinely available in most radiation oncology facilities. In addition, suboptimal cosmetic outcomes have been reported with the external beam technique, possibly related to large post-operative treatment volumes. To address these issues, we designed a phase I dose-escalation protocol to determine the maximally tolerated dose (MTD) of a single radiosurgery treatment delivered preoperatively to the intact tumor plus a small margin.
Materials/Methods: Women aged 55 or older with clinically node negative, ER and/or PR+, HER2-, T1 invasive carcinomas were enrolled (n = 26). Patients with low/intermediate grade in situ disease <2cm were also included (n = 6). Breast MRI was required for target volume delineation. An intensity-modulated treatment plan was designed to deliver 15, 18, or 21Gy in a single fraction. An additional breast MRI, including T1-weighted, T2-weighted, diffusion-weighted and dynamic-contrast enhanced imaging, was obtained prior to lumpectomy which took place within 10 days of radiation treatment. Acute toxicity was assessed 3-4 weeks after radiation and any grade 3/4 toxicity possibly, probably, or definitely related to treatment was considered dose limiting.
Tumor tissue was obtained from diagnostic and lumpectomy specimens. Immunohistochemistry (IHC) for Fas was performed on paraffin-embedded samples before and after radiation. A histoscore was created using the average membrane and cytoplasmic staining intensity multiplied by the percentage of positive cells.
Results: Thirty-two women were treated, 8 each at the 15, 18, and 21Gy dose levels with an additional expansion cohort at the final 21Gy dose level. The maximally tolerated dose was not reached. Three patients required post-operative conventional radiation due to high-risk tumor features (ex. larger primary, nodal involvement).
At a median follow-up of 6.8 months, primarily mild toxicities (grade 1-2 dermatitis, fibrosis, and pain) were noted. At 6 months (n = 20), all reported cosmetic outcomes are excellent or good. At 12 months (n = 10), 80% are excellent or good. Both patients with a fair/poor cosmetic outcome received radiosurgery plus post-operative conventional treatment; one experienced grade 3 breast atrophy. There have been no local or distant recurrences to date.
Post-treatment MRIs were obtained in 20/32 patients, with early indicators of decreased cell density and increased vascular permeability. Sixteen patients had evaluable paired IHC and six demonstrated significant Fas up-regulation after radiation. The mean combined post-treatment histoscore was about twice as high as the mean pre-treatment score.
Conclusion: Preoperative stereotactic radiotherapy to the intact breast tumor can be delivered with widely available clinical tools in a convenient single fraction, and provides a unique opportunity to study breast cancer radiation response. 21Gy did not yield dose-limiting toxicity and will be utilized for future studies.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-14-04.
Collapse
Affiliation(s)
- JK Horton
- Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA
| | - RC Blitzblau
- Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA
| | - S Yoo
- Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA
| | - GS Georgiade
- Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA
| | - J Geradts
- Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA
| | - JA Baker
- Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA
| | - Z Chang
- Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA
| | - G Broadwater
- Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA
| | - W Barry
- Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA
| | - EA Duffy
- Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA
| | - ES Hwang
- Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
16
|
Dorth J, Prosnitz L, Broadwater G, Beaven A, Kelsey C. Radiation Therapy Dose-Response Analysis for Diffuse Large B-cell Lymphoma With a Complete Response to Chemotherapy. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
17
|
Demirci S, Broadwater G, Marks L, Clough R, Prosnitz L. Breast Conservation Therapy (BCT) For Ductal Carcinoma In Situ (DCIS): The Influence of Prognostic Variables. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.1720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
18
|
Demirci S, Broadwater G, Marks LB, Clough R, Prosnitz LR. Breast conservation therapy: The influence of molecules and margins. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Palmer J, Goggins T, Broadwater G, Chao N, Horwitz M, Beaven A, Sullivan K, Coleman RE, Rizzieri D. Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant 2010; 46:847-51. [PMID: 20856212 DOI: 10.1038/bmt.2010.203] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Positron emission tomography (PET) in conjunction with computed tomography is a frequently used modality for staging patients with lymphoma. Utility of PET-computed tomography before or early following auto-SCT has not been as rigorously evaluated. We retrospectively analyzed patients who received auto-SCT for treatment of relapsed or refractory non-Hodgkins lymphoma or Hodgkins disease between the years of 1996 and 2007. Patients who had either a PET scan following salvage chemotherapy within 14 weeks of transplantation (pre-PET), and/or a PET scan 6-14 weeks following transplantation (post-PET) were included. A total of 90 patients were identified for analysis. The median follow-up time is 3.3 years, with a range of 0.13-12.0 years. The median PFS was 4.6 years, and median OS was 5.1 years. At the time of this analysis, 34 patients (37%) experienced disease relapse, and 25 (27%) of the patients died from disease progression. In multivariate Cox proportional hazards analysis, post-PET did not predict for outcome, pre-PET positivity predicted for decrease in PFS. In conclusion, post-PET scan did not predict for PFS or OS in multivariate analysis. Positive pre-PET scan did predict for PFS as seen in previous studies, and may help identify patients who would benefit from innovative post transplant therapies.
Collapse
Affiliation(s)
- J Palmer
- Division of Neoplastic Diseases and Related Disorders, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Brizel D, Yoo D, Carrol M, MacFall J, Barboriak D, Broadwater G, Craciunescu O. 108 poster: Early Therapy Changes in Vascular Permeability Predict Long Term Outcome in Head and Neck Cancer. Radiother Oncol 2010. [DOI: 10.1016/s0167-8140(15)34527-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Harris L, Parker J, Broadwater G, Schulz V, Halligan K, Geyda K, Seidman A, Berry D, Winer E, Hudis C, Krasnitz A, Hicks J, Tuck D, Perou C. Genome-Wide Profiling of Archived Material from CALGB 9840 and 9342 for Paclitaxel (P) and Trastuzumab (T) Response Biomarkers Using Gene Expression and Copy Number Analysis. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-4032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Emerging data suggest that RNA obtained from formalin-fixed, paraffin-embedded (FFPE) tissue can produce reliable gene expression profiles. Archived material from two taxane monotherapy studies, CALGB 9342 (comparison of 3 doses of P) and 9840 (weekly vs. q3 week P)were profiled for gene expression and DNA copy number.Methods: A total of 238 patients had primary tumor blocks available from a combined sample size of 680. DNA and RNA was extracted from 1.5mm punch cores and the Ambion Recover-All kit™. quality was measured by spectrophotometric analysis, Bioanalyzer RNA Integrity Number (RIN), and housekeeping genes (RPL13A and Actin). A custom DASL™ array containing 779 genes in two-fold redundancy was designed with genes selected to represent the PAM50 intrinsic subtypes, the Oncotype Dx Score, the Netherlands prognostic signature and the genes most frequently found on recurrent breast cancer amplicons. Several methods for identifying outliers were evaluated, including principal components analysis, pairwise correlations as well as the reproducibility of the platform based on replicate samples.Results: Adequate RNA was obtained from 237/238 of these cases which ranged in age from 12-18 years. Of these, 215/237DASL arrays passed further quality control measures. Adequate DNA for CGH was obtained from 227/238 samples. Analysis of PAM50 intrinsic subtypes showed an excess of basal-like tumors (30%) in the primary tumors of this metastatic cohort compared with expected frequency in an early stage population. Luminal A tumors were less frequent than expected (20%). Patients with basal-like tumors did far worse than other tumor types for both PFS on P (p=0.015) and OS (p=2.7X10-6), which persisted in multivariable analysis (p=0.0047), however the interaction term was not significant (Wald p=0.26). While basal-like tumors had similar PFS and OS on both weekly and q3 week P, luminal A tumors appear to achieve more benefit from weekly P (p= 0.0041).The HER2-enriched expression subtype had a similar prognosis to Luminal A and B tumors. This appeared to be due to the presence of T, as the addition of this agent improved PFS (p=0.026) and OS (p=2.0X10-4). Of note, some centrally confirmed HER2 FISH amplified tumors were classified into luminal A, B, and basal-like subtypes. These tumors have similar prognoses to the overall group, for example the basal-like and HER2 tumors had a poor prognosis despite T (p=0.00086). This suggests that HER2 FISH positive tumors may behave based on the underlying tumor subtype. Sawtooth genomes (45% vs 15%) were more frequent than predicted by an early stage tumor dataset as were simplex genomes (3% vs 24%). HER2 by FISH and CGH were highly concordant suggesting data on gene amplification from this platform is robust.Conclusions: Gene expression and copy number profiling of FFPE material from archived tumor blocks (>10 years) produces quality data for biomarker discovery in CALGB clinical trial datasets. These tools allow discovery of novel patterns of gene expression and genomic aberrations that are associated with differential response to P and T. Further studies using these platforms should be performed.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4032.
Collapse
Affiliation(s)
| | | | | | | | | | | | - A. Seidman
- 4Memorial Sloan-Kettering Cancer Center, NY,
| | | | - E. Winer
- 6Dana-Farber Cancer Institute, MA,
| | - C. Hudis
- 4Memorial Sloan-Kettering Cancer Center, NY,
| | | | - J. Hicks
- 7Cold Spring Harbour Laboratories, NY,
| | | | - C. Perou
- 2University of North Carolina, NC,
| |
Collapse
|
22
|
Gomez RE, Zakhireh J, Moore D, DeMichele A, Przewoznik J, Ollila D, Frank J, Krontiras H, Montgomery L, Sarode V, Broadwater G, Esserman L, Network TISPYTRIAL. Sentinel node biopsy performed in the neoadjuvant setting for breast cancer: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657). Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #202
Introduction: Controversy remains over whether to perform sentinel node biopsy (SNB) before or after neoadjuvant chemotherapy (NAC). We examined the practice patterns, feasibility, and accuracy of this procedure in high risk breast cancer patients treated with NAC in a multi-institutional correlative science study.
 Methods: Patients with biopsy-proven breast cancer >3 cm enrolled into the I-SPY TRIAL to undergo 4 weeks of anthracycline-based NAC, 4 weeks of taxane treatment, then surgical intervention. Study protocol did not dictate axillary treatment. Timing of SNB was dictated by the surgeon. Practice patterns, outcome of SNB and axillary lymph node dissection (ALND), locoregional recurrence and distant metastases were recorded with a mean follow-up of 2.9 years.
 Results: 237 patients enrolled, 221 completed the trial, 210 had complete data at the time of analysis; Table 1 shows axillary practice patterns.
 
 Overall, 43% had a positive SNB and/or ALND after NAC. 129 (61% of 210) patients presented with clinically positive nodes, 39 of which had a post-NAC SNB. 5/39 had no ALND (all SNB negative). Table 2 shows results for those who had a post-NAC SNB and ALND. For this subset of patients, sentinel node ID, accuracy, and false negative (FN) rates were 80%, 91% and 15% respectively. If SNB was negative, 20% of patients still had a positive ALND. 81 (39% of 210) patients presented with clinically negative nodes, 22 of which had a post-NAC SNB. 8/22 post-NAC SNB patients had no ALND (6 negative, 2 positive for 1mm disease). Table 2 shows results for those who had a post-NAC SNB and ALND. For this subset of patients, sentinel node ID, accuracy, and FN rates were 100%, 100% and 0%.
 
 Overall, there were 26 deaths; 96% occurred in those who presented with clinically positive nodes, 77% had positive post-NAC nodes. A negative axilla post-NAC was predictive of longer DFS over those with axillary disease post-NAC (p<0.05).
 Conclusions: In clinically node negative patients, post-NAC SNB is feasible and accurate before or after NAC. Our data suggests that a post-NAC SNB is sufficient; this avoids an additional operation and allows us to gain information on post-NAC axillary status which is of prognostic significance. In clinically positive patients, SNB does not adequately reflect axillary disease; even when SNB was negative, 20% still had axillary disease. At this time, we recommend that ALND be performed on all clinically node positive patients.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 202.
Collapse
|
23
|
Rimm DL, Broadwater G, Friedman P, Berry D, Seidman A, Hudis C, Winer E, Harris L, Thor A. Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-6046] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #6046
Purpose: The recent ACO/CAP guidelines revised the cut-point for HER2 expression by immunohistochemistry (IHC) from 10% up to 30%. Recently we showed that heterogeneity of expression is a function of the assessed biomarker and, for HER2, >80% area of expression was most prognostic and predictive. Here we test this hypothesis in CALGB 9840, a prospective cooperative group clinical trial of Paclitaxel (P) and Trastuzumab (T).
 Experimental Design: Tissue from 274 cases selected from cases with available slides from the TH arm were first scored by pathologists as 0-3+, but then again scored to assess percentage of tissue staining with prospectively chosen cut points of >10%, >30% or >80%. Response was assessed by modified RECIST criteria, including complete and partial response. Stable disease and progressive disease were considered non-response.
 Results: Amongst the 176 cases treated with P+T there were 90 (52%) responses (PR+CR), 3 cases were unevaluable for response. In the subset of cases treated with T, there was inconsistent differences in the >10% vs the >30% categories but the >80% category was uniformly statistically significantly predictive of response. Receiver Operator Characteristic (ROC) curves constructed to assess prediction of response showed areas under the curves (AUC) of 0.59 for IHC and 0.60 for FISH suggesting both are failed tests for defining an optimal cut-point. However, selecting only the cases scored as 3+ shows an AUC of 0.72 and the optimal cut-point is for the test is at 95% positive 3+ HER2 staining. This modification of the cut-point would have denied T to 6 of the 49 patients who responded to therapy in the 3+ group. However, there were also 41 (of 86) patients in the 0,1+ and 2+ groups that responded to therapy, raising the possibility that the response in those 6 patients may have been unrelated to T therapy.
 Conclusions: When using clinical outcome to assess the value of the current tests for prediction of response to T, ROC curves suggest that both the old and new HER2 tests fail at defining an optimal cut-point. However, using only strongly positive cases (3+), an acceptable test can be achieved which is maximized at 95% area of expression. This cut-point, while statistically rigorous, is limited by the fact that the patients were treated with both P and T. This result suggests a similar analysis is warranted on a larger cohort of T treated patients, perhaps in the adjuvant or neoadjuvant setting. The availability of other options for HER2 amplified cases (ie lapatinib) and the increased use of T in the adjuvant setting warrant optimization of tests for the best possible patient selection.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6046.
Collapse
Affiliation(s)
- DL Rimm
- 1 Yale University School of Medicine, New Haven, CT
| | | | | | - D Berry
- 5 MD Anderson Cancer Center, Houston, TX
| | - A Seidman
- 4 Memorial Sloan Kettering Cancer Center, New York, NY
| | - C Hudis
- 4 Memorial Sloan Kettering Cancer Center, New York, NY
| | - E Winer
- 7 Dana Farber Cancer Institute, Boston, MA
| | - L Harris
- 1 Yale University School of Medicine, New Haven, CT
| | - A Thor
- 6 University of Colorado, Denver, CO
| |
Collapse
|
24
|
Kaufman PA, Broadwater G, Lezon-Geyda K, Dressler LG, Berry D, Friedman P, Winer EP, Hudis C, Ellis MJ, Seidman AD, Harris LN. CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1009] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1009 Background: Accurate assessment of HER-2 is critical in MBC and predicts benefit from T. We have previously shown low level amplification of HER-2 associated with ch17 polysomy is common in IHC 2+ cases that are FISH(-). However, the clinical relevance of this is unknown. Methods: CALGB 150002, a correlative companion to 9840, was designed to assess the predictive role of HER-2 in MBC pts treated with weekly vs q 3W P ± T. Pts HER-2(-) locally were randomized to ±T. 585 pts were enrolled in 9840; 304 blocks were available for central analysis with DAKO HercepTest (IHC) and Pathvysion (FISH). Logistic regression was used to test HER-2:ch17 ratio and HER-2 copy # as predictor of response rate (RR) to T in HER-2(+) pts. 1-sided Fisher’s Exact Test was used to compare RR of P vs P+T in pts with ch17 polysomy on central testing (>2.2 copies ch17/cell), but defined as HER-2(-) locally and randomized to T. Results: In pts HER-2(+) locally, FISH is a significant predictor of RR to P+T. A higher HER-2:ch17 ratio is associated with a higher RR by logistic regression (p=0.033, n=95). No interaction is seen between HER-2 and P schedule, p=0.71. On central testing of cases IHC(-) locally, 16/140 (11%) were IHC 3+ and 5/133 (4%) HER-2 amplified. In 21 HER-2(-) cases reclassified as HER-2 3+ or FISH (+) centrally, we do not find a difference in RR to P vs P+T. However among 133 cases HER-2(-) locally and central FISH(-) we find 32 with ch17 polysomy (copy # ch17 = 2.2); 12 treated with P alone, and 19 with P+T (see table for RR). Conclusions: These data suggest a higher RR to P+T in HER-2(+) pts with a higher HER-2:ch17 ratio, consistent with a relationship between RR to T and HER-2 copy #. In FISH(-) cases we note an increased RR to P+T vs P in cases with ch17 polysomy, typically reported clinically as HER-2(-). This analysis suggests that T might be effective in a subpopulation of breast cancer conventionally defined as HER-2(-), but in fact displaying low level HER-2 amplification. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- P. A. Kaufman
- Dartmouth Hitchcock Medical Center, Lebanon, NH; Duke University Medical Center, Durham, NC; Yale School of Medicine, New Haven, CT; Lineberger Cancer Center, Univ of North Carolina, Chapel Hill, NC; MD Anderson Cancer Center, CALGB Statistical Ctr, Houston, TX; CALGB, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University, St. Louis, MO
| | - G. Broadwater
- Dartmouth Hitchcock Medical Center, Lebanon, NH; Duke University Medical Center, Durham, NC; Yale School of Medicine, New Haven, CT; Lineberger Cancer Center, Univ of North Carolina, Chapel Hill, NC; MD Anderson Cancer Center, CALGB Statistical Ctr, Houston, TX; CALGB, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University, St. Louis, MO
| | - K. Lezon-Geyda
- Dartmouth Hitchcock Medical Center, Lebanon, NH; Duke University Medical Center, Durham, NC; Yale School of Medicine, New Haven, CT; Lineberger Cancer Center, Univ of North Carolina, Chapel Hill, NC; MD Anderson Cancer Center, CALGB Statistical Ctr, Houston, TX; CALGB, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University, St. Louis, MO
| | - L. G. Dressler
- Dartmouth Hitchcock Medical Center, Lebanon, NH; Duke University Medical Center, Durham, NC; Yale School of Medicine, New Haven, CT; Lineberger Cancer Center, Univ of North Carolina, Chapel Hill, NC; MD Anderson Cancer Center, CALGB Statistical Ctr, Houston, TX; CALGB, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University, St. Louis, MO
| | - D. Berry
- Dartmouth Hitchcock Medical Center, Lebanon, NH; Duke University Medical Center, Durham, NC; Yale School of Medicine, New Haven, CT; Lineberger Cancer Center, Univ of North Carolina, Chapel Hill, NC; MD Anderson Cancer Center, CALGB Statistical Ctr, Houston, TX; CALGB, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University, St. Louis, MO
| | - P. Friedman
- Dartmouth Hitchcock Medical Center, Lebanon, NH; Duke University Medical Center, Durham, NC; Yale School of Medicine, New Haven, CT; Lineberger Cancer Center, Univ of North Carolina, Chapel Hill, NC; MD Anderson Cancer Center, CALGB Statistical Ctr, Houston, TX; CALGB, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University, St. Louis, MO
| | - E. P. Winer
- Dartmouth Hitchcock Medical Center, Lebanon, NH; Duke University Medical Center, Durham, NC; Yale School of Medicine, New Haven, CT; Lineberger Cancer Center, Univ of North Carolina, Chapel Hill, NC; MD Anderson Cancer Center, CALGB Statistical Ctr, Houston, TX; CALGB, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University, St. Louis, MO
| | - C. Hudis
- Dartmouth Hitchcock Medical Center, Lebanon, NH; Duke University Medical Center, Durham, NC; Yale School of Medicine, New Haven, CT; Lineberger Cancer Center, Univ of North Carolina, Chapel Hill, NC; MD Anderson Cancer Center, CALGB Statistical Ctr, Houston, TX; CALGB, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University, St. Louis, MO
| | - M. J. Ellis
- Dartmouth Hitchcock Medical Center, Lebanon, NH; Duke University Medical Center, Durham, NC; Yale School of Medicine, New Haven, CT; Lineberger Cancer Center, Univ of North Carolina, Chapel Hill, NC; MD Anderson Cancer Center, CALGB Statistical Ctr, Houston, TX; CALGB, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University, St. Louis, MO
| | - A. D. Seidman
- Dartmouth Hitchcock Medical Center, Lebanon, NH; Duke University Medical Center, Durham, NC; Yale School of Medicine, New Haven, CT; Lineberger Cancer Center, Univ of North Carolina, Chapel Hill, NC; MD Anderson Cancer Center, CALGB Statistical Ctr, Houston, TX; CALGB, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University, St. Louis, MO
| | - L. N. Harris
- Dartmouth Hitchcock Medical Center, Lebanon, NH; Duke University Medical Center, Durham, NC; Yale School of Medicine, New Haven, CT; Lineberger Cancer Center, Univ of North Carolina, Chapel Hill, NC; MD Anderson Cancer Center, CALGB Statistical Ctr, Houston, TX; CALGB, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Washington University, St. Louis, MO
| |
Collapse
|
25
|
Vredenburgh JJ, Madan B, Coniglio D, Ross M, Broadwater G, Niedzwiecki D, Edwards J, Marks L, Vandemark R, McDonald C, Affronti ML, Peters WP. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant 2006; 37:1009-15. [PMID: 16633363 DOI: 10.1038/sj.bmt.1705367] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The prognosis for patients with metastatic breast cancer remains poor. Metastatic breast cancer confined to the bones may have a better prognosis, especially hormone receptor-positive disease. We performed a prospective, randomized clinical trial to compare immediate consolidation with high-dose chemotherapy and hematopoietic support versus observation with high-dose consolidation at the time of disease progression in women with metastatic breast cancer and only bone metastases. The patients received chemotherapy with doxorubicin, 5-fluorouracil and methotrexate before randomization. In all, 85 patients were enrolled and 69 were randomized. The median follow-up is 8.1 years from randomization. The median event-free survival (EFS) for the immediate transplant arm is 12 months and for the observation arm is 4.3 months (P<0.0001). The median overall survival for the immediate transplant arm is 2.97 years and for the observation arm 1.81 years, a difference that is not statistically significant. Immediate high-dose chemotherapy and radiation therapy as consolidation offers a clinically and statistically significant improvement in EFS compared with radiation therapy alone following induction chemotherapy for women with metastatic breast cancer confined to the bones.
Collapse
Affiliation(s)
- J J Vredenburgh
- Division of Medical Oncology/Transplantation, Duke University Medical Center, Durham, NC 27710, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Hayes DF, Thor A, Dressler L, Weaver D, Broadwater G, Goldstein L, Martino S, Ingle J, Henderson IC, Berry D. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.510] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
510 Background: CALGB 9344 showed 4 cycles of paclitaxel (T) after 4 cycles of doxorubicin/cyclophosphamide (AC) improved disease-free (DFS) and overall survival (OS) compared to 4 cycles of AC. Higher dose of A had no benefit (Henderson JCO ’03). Prior studies suggest HER2 is associated with benefit from standard vs low dose of C&A (Dressler JCO ’05). We hypothesized that HER2 might predict benefit from higher dose of A or from T, and that HER2 might refine the observed negative interaction of T with estrogen receptor (ER). Methods: 3121 node + women in CALGB 9344 received 4 q3wk cycles of AC (A: 60, 75, or 90 mg/m2) and then 4 cycles of T (175 mg/m2 q3wk) or no T. Blocks were collected from ∼2800 subjects. 2 sets of 750 patients each were randomly selected from these cases: Set 1 to develop hypotheses; Set 2 for validation. Tissue specimens were available from 643 (set1) and 679 (set2) cases (20% & 22% total enrolled in 9344 respectively). HER2 was evaluated by FISH and by IHC (by antibody cb11 and by Herceptest). Statistical analyses used Cox proportional hazards models, including interaction terms, and Kaplan-Meier estimates for comparing 5-yr DFS by treatment group. Results: In Set 1, all 3 assays suggested that T improved DFS for HER2+ but not for HER2-. For this single set the interaction was not statistically significant. There appeared to be an interaction of HER2, T and ER. IHC using cb11 was applied to Set 2, revealing nearly identical results. In the two sets combined (n=1322), the interaction between HER2 and T was statistically significant (p=0.013). The 3-way interaction of HER2, ER and T was hypothesis-generating and not tested statistically. Differences in 5-yr DFS rates (95% CI) for T vs. no T by HER2 and ER (both sets combined) There was no interaction between HER2 and dose of A. Conclusions: These results suggest that the benefit of adding T to AC is greater for HER2+ tumors, even if ER+, while T was of no apparent benefit in the ER+, HER2- group. Further validation is needed from remaining cases in 9344 and from other trials involving T. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- D. F. Hayes
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - A. Thor
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - L. Dressler
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - D. Weaver
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - G. Broadwater
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - L. Goldstein
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - S. Martino
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - J. Ingle
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - I. C. Henderson
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| | - D. Berry
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of North Carolina, Chapel Hill, NC; University of Vermont, Burlington, VT; Duke University, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Cancer Institute Medical Group, Santa Monica, CA; Mayo Clinic, Rochester, MN; University of California San Francisco, San Francisco, CA; M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
27
|
Prasad V, Chen DF, Reinsmoen N, Broadwater G, Chao N, Rizzieri D. Impact of donor KIR genotype and recipient HLA ligand incompatibility on relapse related mortality and acute graft versus host disease in high-risk patients undergoing haploidentical non-myeloablative peripheral blood stem cell transplants: Differences between lymphoid and myeloid malignancies. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Seidman AD, Broadwater G, Carney W, Dressler L, Berry D, Norton L, Hudis C, Winer E, Ellis M, Harris L. Serum HER2 extracellular domain (ECD) levels and efficacy of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic breast cancer (MBC): CALGB 150002/9840. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.558] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. D. Seidman
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Duke Univ Sch of Medicine, Durham, NC; Oncogene Science, Cambridge, MA; Univ of North Carolina, Chapel Hill, NC; M.D. Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Inst, Boston, MA; Washington Univ of St. Louis, St Louis, MO
| | - G. Broadwater
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Duke Univ Sch of Medicine, Durham, NC; Oncogene Science, Cambridge, MA; Univ of North Carolina, Chapel Hill, NC; M.D. Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Inst, Boston, MA; Washington Univ of St. Louis, St Louis, MO
| | - W. Carney
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Duke Univ Sch of Medicine, Durham, NC; Oncogene Science, Cambridge, MA; Univ of North Carolina, Chapel Hill, NC; M.D. Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Inst, Boston, MA; Washington Univ of St. Louis, St Louis, MO
| | - L. Dressler
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Duke Univ Sch of Medicine, Durham, NC; Oncogene Science, Cambridge, MA; Univ of North Carolina, Chapel Hill, NC; M.D. Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Inst, Boston, MA; Washington Univ of St. Louis, St Louis, MO
| | - D. Berry
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Duke Univ Sch of Medicine, Durham, NC; Oncogene Science, Cambridge, MA; Univ of North Carolina, Chapel Hill, NC; M.D. Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Inst, Boston, MA; Washington Univ of St. Louis, St Louis, MO
| | - L. Norton
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Duke Univ Sch of Medicine, Durham, NC; Oncogene Science, Cambridge, MA; Univ of North Carolina, Chapel Hill, NC; M.D. Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Inst, Boston, MA; Washington Univ of St. Louis, St Louis, MO
| | - C. Hudis
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Duke Univ Sch of Medicine, Durham, NC; Oncogene Science, Cambridge, MA; Univ of North Carolina, Chapel Hill, NC; M.D. Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Inst, Boston, MA; Washington Univ of St. Louis, St Louis, MO
| | - E. Winer
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Duke Univ Sch of Medicine, Durham, NC; Oncogene Science, Cambridge, MA; Univ of North Carolina, Chapel Hill, NC; M.D. Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Inst, Boston, MA; Washington Univ of St. Louis, St Louis, MO
| | - M. Ellis
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Duke Univ Sch of Medicine, Durham, NC; Oncogene Science, Cambridge, MA; Univ of North Carolina, Chapel Hill, NC; M.D. Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Inst, Boston, MA; Washington Univ of St. Louis, St Louis, MO
| | - L. Harris
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Duke Univ Sch of Medicine, Durham, NC; Oncogene Science, Cambridge, MA; Univ of North Carolina, Chapel Hill, NC; M.D. Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Inst, Boston, MA; Washington Univ of St. Louis, St Louis, MO
| |
Collapse
|
29
|
Harris LN, Perou C, Szallasi Z, Eklund A, Carter S, You F, Broadwater G, Monovich L, Winer E, Erlander M, Ellis M. Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: Results from a pilot study in CALGB 9342. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. N. Harris
- Dana-Farber Cancer Inst, Boston, MA; Univ of North Carolina, Chapel Hill, NC; Children’s Hosp, Boston, MA; Duke Univ, Durham, NC; Univ of Chicago, Chicago, IL; Arcturus Inc., Los Angeles, CA; Washington Univ, St Louis, MO
| | - C. Perou
- Dana-Farber Cancer Inst, Boston, MA; Univ of North Carolina, Chapel Hill, NC; Children’s Hosp, Boston, MA; Duke Univ, Durham, NC; Univ of Chicago, Chicago, IL; Arcturus Inc., Los Angeles, CA; Washington Univ, St Louis, MO
| | - Z. Szallasi
- Dana-Farber Cancer Inst, Boston, MA; Univ of North Carolina, Chapel Hill, NC; Children’s Hosp, Boston, MA; Duke Univ, Durham, NC; Univ of Chicago, Chicago, IL; Arcturus Inc., Los Angeles, CA; Washington Univ, St Louis, MO
| | - A. Eklund
- Dana-Farber Cancer Inst, Boston, MA; Univ of North Carolina, Chapel Hill, NC; Children’s Hosp, Boston, MA; Duke Univ, Durham, NC; Univ of Chicago, Chicago, IL; Arcturus Inc., Los Angeles, CA; Washington Univ, St Louis, MO
| | - S. Carter
- Dana-Farber Cancer Inst, Boston, MA; Univ of North Carolina, Chapel Hill, NC; Children’s Hosp, Boston, MA; Duke Univ, Durham, NC; Univ of Chicago, Chicago, IL; Arcturus Inc., Los Angeles, CA; Washington Univ, St Louis, MO
| | - F. You
- Dana-Farber Cancer Inst, Boston, MA; Univ of North Carolina, Chapel Hill, NC; Children’s Hosp, Boston, MA; Duke Univ, Durham, NC; Univ of Chicago, Chicago, IL; Arcturus Inc., Los Angeles, CA; Washington Univ, St Louis, MO
| | - G. Broadwater
- Dana-Farber Cancer Inst, Boston, MA; Univ of North Carolina, Chapel Hill, NC; Children’s Hosp, Boston, MA; Duke Univ, Durham, NC; Univ of Chicago, Chicago, IL; Arcturus Inc., Los Angeles, CA; Washington Univ, St Louis, MO
| | - L. Monovich
- Dana-Farber Cancer Inst, Boston, MA; Univ of North Carolina, Chapel Hill, NC; Children’s Hosp, Boston, MA; Duke Univ, Durham, NC; Univ of Chicago, Chicago, IL; Arcturus Inc., Los Angeles, CA; Washington Univ, St Louis, MO
| | - E. Winer
- Dana-Farber Cancer Inst, Boston, MA; Univ of North Carolina, Chapel Hill, NC; Children’s Hosp, Boston, MA; Duke Univ, Durham, NC; Univ of Chicago, Chicago, IL; Arcturus Inc., Los Angeles, CA; Washington Univ, St Louis, MO
| | - M. Erlander
- Dana-Farber Cancer Inst, Boston, MA; Univ of North Carolina, Chapel Hill, NC; Children’s Hosp, Boston, MA; Duke Univ, Durham, NC; Univ of Chicago, Chicago, IL; Arcturus Inc., Los Angeles, CA; Washington Univ, St Louis, MO
| | - M. Ellis
- Dana-Farber Cancer Inst, Boston, MA; Univ of North Carolina, Chapel Hill, NC; Children’s Hosp, Boston, MA; Duke Univ, Durham, NC; Univ of Chicago, Chicago, IL; Arcturus Inc., Los Angeles, CA; Washington Univ, St Louis, MO
| |
Collapse
|
30
|
Harris L, Dressler L, Cowan D, Berry D, Cirrincione C, Broadwater G, Muss H, Hayes D, Ellis M. The role of HER-2 + Topo IIα amplification in predicting benefit from CAF dose escalation-CALGB 8541. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Harris
- Dana Farber Cancer Institute, Boston, MA; University of North Carolina, Chapel Hill, NC; CALGB, Chicago, IL; Duke University Cancer Center, Durham, NC
| | - L. Dressler
- Dana Farber Cancer Institute, Boston, MA; University of North Carolina, Chapel Hill, NC; CALGB, Chicago, IL; Duke University Cancer Center, Durham, NC
| | - D. Cowan
- Dana Farber Cancer Institute, Boston, MA; University of North Carolina, Chapel Hill, NC; CALGB, Chicago, IL; Duke University Cancer Center, Durham, NC
| | - D. Berry
- Dana Farber Cancer Institute, Boston, MA; University of North Carolina, Chapel Hill, NC; CALGB, Chicago, IL; Duke University Cancer Center, Durham, NC
| | - C. Cirrincione
- Dana Farber Cancer Institute, Boston, MA; University of North Carolina, Chapel Hill, NC; CALGB, Chicago, IL; Duke University Cancer Center, Durham, NC
| | - G. Broadwater
- Dana Farber Cancer Institute, Boston, MA; University of North Carolina, Chapel Hill, NC; CALGB, Chicago, IL; Duke University Cancer Center, Durham, NC
| | - H. Muss
- Dana Farber Cancer Institute, Boston, MA; University of North Carolina, Chapel Hill, NC; CALGB, Chicago, IL; Duke University Cancer Center, Durham, NC
| | - D. Hayes
- Dana Farber Cancer Institute, Boston, MA; University of North Carolina, Chapel Hill, NC; CALGB, Chicago, IL; Duke University Cancer Center, Durham, NC
| | - M. Ellis
- Dana Farber Cancer Institute, Boston, MA; University of North Carolina, Chapel Hill, NC; CALGB, Chicago, IL; Duke University Cancer Center, Durham, NC
| |
Collapse
|
31
|
Dressler LG, Broadwater G, Berry D, Cirrincione C, Cowan D, Harris L, Moore D, Muss H, Hayes D, Ellis M. A comparison of two HER2 FISH methods to measure HER2 amplification and predict clinical outcome. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. G. Dressler
- University of North Carolina, Chapel Hill, NC; University of Chicago, Chicago, IL; M. D. Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA; University of Vermont, Burlington, VT; University of Michigan, Ann Arbor, MI; University of Washington, St. Louis, MO
| | - G. Broadwater
- University of North Carolina, Chapel Hill, NC; University of Chicago, Chicago, IL; M. D. Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA; University of Vermont, Burlington, VT; University of Michigan, Ann Arbor, MI; University of Washington, St. Louis, MO
| | - D. Berry
- University of North Carolina, Chapel Hill, NC; University of Chicago, Chicago, IL; M. D. Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA; University of Vermont, Burlington, VT; University of Michigan, Ann Arbor, MI; University of Washington, St. Louis, MO
| | - C. Cirrincione
- University of North Carolina, Chapel Hill, NC; University of Chicago, Chicago, IL; M. D. Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA; University of Vermont, Burlington, VT; University of Michigan, Ann Arbor, MI; University of Washington, St. Louis, MO
| | - D. Cowan
- University of North Carolina, Chapel Hill, NC; University of Chicago, Chicago, IL; M. D. Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA; University of Vermont, Burlington, VT; University of Michigan, Ann Arbor, MI; University of Washington, St. Louis, MO
| | - L. Harris
- University of North Carolina, Chapel Hill, NC; University of Chicago, Chicago, IL; M. D. Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA; University of Vermont, Burlington, VT; University of Michigan, Ann Arbor, MI; University of Washington, St. Louis, MO
| | - D. Moore
- University of North Carolina, Chapel Hill, NC; University of Chicago, Chicago, IL; M. D. Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA; University of Vermont, Burlington, VT; University of Michigan, Ann Arbor, MI; University of Washington, St. Louis, MO
| | - H. Muss
- University of North Carolina, Chapel Hill, NC; University of Chicago, Chicago, IL; M. D. Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA; University of Vermont, Burlington, VT; University of Michigan, Ann Arbor, MI; University of Washington, St. Louis, MO
| | - D. Hayes
- University of North Carolina, Chapel Hill, NC; University of Chicago, Chicago, IL; M. D. Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA; University of Vermont, Burlington, VT; University of Michigan, Ann Arbor, MI; University of Washington, St. Louis, MO
| | - M. Ellis
- University of North Carolina, Chapel Hill, NC; University of Chicago, Chicago, IL; M. D. Anderson Cancer Center, Houston, TX; Dana Farber Cancer Institute, Boston, MA; University of Vermont, Burlington, VT; University of Michigan, Ann Arbor, MI; University of Washington, St. Louis, MO
| |
Collapse
|
32
|
Lin NU, Broadwater G, Dressler LG, Schnitt S, Lara J, Bleiweiss I, Ngo T, Miron A, Winer E, Harris LN. The predictive value of HER2 and p53 on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from CALGB 9342. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- N. U. Lin
- Cancer and Leukemia Group B, Chicago, IL
| | | | | | - S. Schnitt
- Cancer and Leukemia Group B, Chicago, IL
| | - J. Lara
- Cancer and Leukemia Group B, Chicago, IL
| | | | - T. Ngo
- Cancer and Leukemia Group B, Chicago, IL
| | - A. Miron
- Cancer and Leukemia Group B, Chicago, IL
| | - E. Winer
- Cancer and Leukemia Group B, Chicago, IL
| | | |
Collapse
|
33
|
McGaughey DS, Nikcevich DA, Long GD, Vredenburgh JJ, Rizzieri D, Smith CA, Broadwater G, Loftis JS, McDonald C, Morris AK, Folz RF, Chao NF. Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 2002; 7:274-8. [PMID: 11400949 DOI: 10.1053/bbmt.2001.v7.pm11400949] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
PURPOSE To evaluate the efficacy of inhaled fluticasone propionate (Flovent) as prophylaxis against delayed pulmonary toxicity syndrome (DPTS) and decline in pulmonary function in breast cancer patients undergoing high-dose chemotherapy with the conditioning regimen of cyclophosphamide, cisplatin, and carmustine (CPB) followed by autologous stem cell transplantation (ASCT). PATIENTS AND METHODS Sixty-three consecutive patients with multinode-positive or metastatic breast cancer undergoing high-dose chemotherapy with CPB and ASCT who were treated at the Duke University Adult Bone Marrow Transplant Program. All patients were started on inhaled fluticasone propionate, 880 microg every 12 hours, for 12 weeks from the start date of their CPB conditioning regimen. Pulmonary function tests (PFTs) with a single-breath diffusing capacity of carbon monoxide (DLCO) were performed pre-ASCT as well as approximately 6 and 12 weeks post-ASCT. DPTS was defined as follows: (1) development of a nonproductive cough and dyspnea with or without fever, plus a fall in DLCO to less than 60% predicted; or (2) decline in DLCO to less than 50% predicted with or without symptoms. RESULTS Pulmonary function tests were done on all patients pre-ASCT, on 56 of the 63 patients at a median of 44 days (range, 25 to 73 days) post-ASCT, and on 51 of the 63 patients at a median of 96 days (range, 50 to 190 days) post-ASCT. The PFTs showed an average of an 8% (+/-26%) and 21% (+/-22%) decline in DLCO. These declines compare favorably with our historical control group of 45 consecutive breast cancer patients undergoing ASCT with CPB as a conditioning regimen, who experienced average declines in DLCO of 29% (+/-18%) (P < .001) and 33% (+/-18%) (P < .001) at comparable time periods post-ASCT. Delayed pulmonary toxicity syndrome occurred in 35% of treated patients compared to 73% of the historical controls (P = .0003). No patients died of DPTS or pulmonary problems, and there were no fungal pneumonias. CONCLUSION Inhaled fluticasone propionate may decrease the incidence of DPTS in patients treated with CPB as a conditioning regimen for ASCT, as well as help to preserve pulmonary function as measured by DLCO. These results are worthy of further study in a randomized clinical trial.
Collapse
Affiliation(s)
- D S McGaughey
- Adult Bone Marrow and Stem Cell Transplant Program, Duke University Medical Center, Durham, North Carolina 27710, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001; 7:2703-11. [PMID: 11555582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
PURPOSE The HER-2/erbB-2/c-neu (HER-2) proto-oncogene is a M(r) 185,000 transmembrane tyrosine kinase that is amplified and/or overexpressed by 20-40% of breast cancers. HER-2 has been associated with worse prognosis and resistance or sensitivity to specific treatment. We evaluated circulating levels of extracellular domain of HER-2 (ECD/HER-2) in metastatic breast cancer patients and investigated the prognostic and predictive significance of circulating HER-2 levels regarding endocrine therapy or chemotherapy. EXPERIMENTAL DESIGN Plasma samples from 242 patients were assayed for circulating ECD/HER-2 levels, using a sandwich enzyme immunoassay. ECD/HER-2 was correlated with clinical data gathered from these patients while they were participating in prospective Cancer and Leukemia Group B (CALGB) therapeutic protocols for metastatic breast cancer. RESULTS Eighty-nine (37%) of 242 patients had elevated ECD/HER-2 levels (> or =10.5 ng/ml). ECD/HER-2 was significantly associated with tumor burden, progesterone receptor levels, and presence of visceral metastases. Patients with elevated pretreatment levels had a significantly shorter OS but not time-to-progression than did those with ECD/HER-2 levels <10.5 ng/ml in univariate analysis. In univariate but not multivariate subset analyses, among patients treated with endocrine therapy (megestrol acetate), elevated initial ECD/HER-2 was associated with worse OS compared with nonelevated patients. However, among patients treated with chemotherapy (mainly anthracycline-containing regimens), OS did not differ significantly. Rates of response to either endocrine therapy or chemotherapy were similar for patients with elevated and nonelevated ECD/HER-2 levels. CONCLUSIONS ECD/HER-2 levels are elevated in 35-40% of patients with metastatic breast cancer. Elevated ECD/HER-2 levels are associated with a poorer prognosis in these patients. However, no predictive role for ECD/HER-2 was identified, either for endocrine therapy or for anthracycline-based chemotherapy in the metastatic setting.
Collapse
Affiliation(s)
- D F Hayes
- Georgetown University Medical Center, Washington, DC 20007, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Connor CE, Norris JD, Broadwater G, Willson TM, Gottardis MM, Dewhirst MW, McDonnell DP. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res 2001; 61:2917-22. [PMID: 11306468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
Tamoxifen inhibits estrogen receptor (ER) transcriptional activity by competitively inhibiting estradiol binding and inducing conformational changes in the receptor that may prevent its interaction with coactivators. In bone, the cardiovascular system, and some breast tumors, however, tamoxifen exhibits agonist activity, suggesting that the tamoxifen-ER complex is not recognized identically in all cells. We used phage display to demonstrate that the antiestrogen GW5638 induces a unique structural change in the ER. The biological significance of this conformational change was revealed in studies that demonstrated that tamoxifen-resistant breast tumor explants are not cross-resistant to GW5638. Because of these properties, this drug is currently being developed as a potential therapeutic for tamoxifen-resistant breast cancers.
Collapse
Affiliation(s)
- C E Connor
- Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina 27710, USA
| | | | | | | | | | | | | |
Collapse
|
36
|
Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, Everett T, Harpole D, Moore MB, Berry DA, Rizzeri D, Vredenburgh JJ, Bentley RC. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001; 19:1698-706. [PMID: 11250999 DOI: 10.1200/jco.2001.19.6.1698] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE HER-2 is overexpressed in 20% to 30% of human breast cancer and is associated with poor outcome. Studies suggest an association between HER-2 overexpression and resistance to alkylating agents. To further evaluate this relationship, we assessed the interaction of HER-2, measured by different methods, and outcome after dose intensification with alkylating agents in metastatic breast cancer. PATIENTS AND METHODS From 1988 to 1995 at Duke University, 425 patients with metastatic breast cancer were enrolled in a study of high-dose alkylating agents (HDC) with autologous cellular support after doxorubicin-based therapy (AFM). HER-2 was measured in serum for shed extracellular domain (ECD) and in tissue by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). RESULTS HER-2 ECD was positive in 29% (19 of 65) of patients pre-AFM and in 11.7% (34 of 290) pre-HDC. Higher pre-AFM and higher pre-HDC HER-2 ECD predicted worse overall survival (P =.045 and P =.0096, respectively). HER-2 overexpression by IHC and FISH showed no correlation with worse disease-free survival or overall survival. FISH and ECD were highly specific for IHC (97.3% and 97.7% respectively). However, ECD had a low sensitivity for IHC-only 22% of patients with HER-2 in the primary tumor shed ECD into the serum. CONCLUSION These data suggest that the method of measuring HER-2 is important in predicting clinical outcome. HER2 ECD may identify a poor prognosis subgroup of HER-2-positive tumors. Lack of association of HER2 by IHC/FISH with worse outcome suggests that therapy with AFM and/or HDC therapy may be able to overcome the effect of this prognostic factor or it may not be a prognostic factor in this setting.
Collapse
Affiliation(s)
- L N Harris
- Dana-Farber Cancer Institute, Boston, MA 02115, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Blackwell KL, Haroon ZA, Shan S, Saito W, Broadwater G, Greenberg CS, Dewhirst MW. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 2000; 6:4359-64. [PMID: 11106254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
Inhibition of tumor angiogenesis is a therapeutic strategy that can inhibit tumor growth and metastases. The aim of this study was to determine whether the estrogen receptor (ER) ligand drug tamoxifen has antiangiogenic effects. We used three different models of angiogenesis, including measurement of microvessel densities in murine tumors, ex vivo aortic ring assays, and corneal pocket assays. ER-negative fibrosarcoma tumors in tamoxifen-treated ovariectomized rats had significantly less vessel formation compared with untreated animals (median microvessel density, 53.6 versus 94.3 counts/per x 200 field; P = 0.002). Rat aortic rings treated with tamoxifen at several different concentrations demonstrated significantly less vascular sprouting than control rings (P = 0.0001). Corneal pocket assays performed in tamoxifen-treated rats compared with control and estrogen-treated rats demonstrated decreased vascular length (0.88 mm versus 1.26 mm versus 1.47 mm; P = 0.022) and vessel area (21% versus 34% versus 47%; P = 0.018). These three animal models all showed significant inhibition of angiogenesis by tamoxifen and suggest a possible contributory mechanism of ER-independent manipulation by tamoxifen in the treatment and prevention of breast cancer. These studies raise the question as to whether or not newer ER ligand drugs might possess even more potent antiangiogenic effects, which in turn could lead to the broadening of the clinical usefulness of these compounds in a number of diseases. More importantly, these studies suggest that the antiangiogenic effects of tamoxifen are due, in part, to ER-independent mechanisms.
Collapse
Affiliation(s)
- K L Blackwell
- Department of Medical Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
| | | | | | | | | | | | | |
Collapse
|
38
|
Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000; 18:3471-9. [PMID: 11032587 DOI: 10.1200/jco.2000.18.20.3471] [Citation(s) in RCA: 130] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE An association between the overexpression of proto-oncogene HER-2/neu and resistance to tamoxifen in estrogen receptor (ER)-positive primary and metastatic breast cancer has been suggested. We examine a possible interaction between HER-2/neu or p53 expression and tamoxifen effectiveness in patients with ER-positive, node-positive disease treated with cyclophosphamide, doxorubicin, and fluorouracil in a large adjuvant chemotherapy trial (Cancer and Leukemia Group B [CALGB] 8541). Tamoxifen assignment was not randomized-physician discretion was used for premenopausal and postmenopausal women. Trial protocol then specified assignment to postmenopausal women with ER-positive tumors, although not all took tamoxifen. PATIENTS AND METHODS CALGB 8541 assessed HER-2/neu expression in patients with ER-positive disease by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) and amplification by differential polymerase chain reaction (PCR). IHC assessed expression of p53. Univariate and multivariate proportional hazards models assessed tamoxifen-HER-2/neu status interactions and tamoxifen-p53 status interactions. RESULTS HER-2/neu status was available for 651 patients with ER-positive disease; 650, 608, and 353 patients were assessed by IHC, PCR, and FISH, respectively. Approximately one half received tamoxifen. Reduction in risk of disease recurrence or death resulting from tamoxifen was approximately 37% (32% with overexpression and 39% with normal expression of HER-2/neu; n = 155 by IHC). The tamoxifen-HER-2/neu status interaction was not significant in multivariate analysis of all three HER-2/neu assessment methods. Tamoxifen-p53 interaction did not significantly predict outcome. CONCLUSION Disease-free and overall survival benefit of tamoxifen in patients with ER-positive, node-positive breast cancer does not depend on HER-2/neu or p53 status. Our data suggest that neither HER-2/neu nor p53 expression should be used to determine assignment of tamoxifen.
Collapse
Affiliation(s)
- D A Berry
- University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Guidi AJ, Berry DA, Broadwater G, Perloff M, Norton L, Barcos MP, Hayes DF. Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst 2000; 92:486-92. [PMID: 10716967 DOI: 10.1093/jnci/92.6.486] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Microvessel density (MVD) is a measure of the extent of new blood vessel growth or angiogenesis, which is required for tumor progression. Increased MVD in primary breast cancers appears to adversely affect disease-free survival and overall survival in patients with breast cancer. However, the clinical implications of angiogenesis in breast cancer metastases have not been well studied. The purpose of this study was to compare intratumoral MVD in primary breast cancer tissues with MVD in axillary lymph node metastases and to evaluate the relationships among primary- and metastatic-tumor MVD, disease-free survival, and overall survival in patients with lymph node-positive, stage II breast cancer who were treated with adjuvant chemotherapy in Cancer and Leukemia Group B Protocol 8082. METHODS Immunostaining for factor VIII-related antigen was performed on tissue sections from 47 primary tumors and 91 axillary lymph nodes containing metastases from 110 patients with lymph node-positive breast cancer. Sections were examined for the presence or absence of focal areas of relatively intense neovascularization (vascular hot spots), and a quantitative assessment of intratumoral MVD was performed. RESULTS The presence of vascular hot spots in axillary lymph node metastases, but not primary breast cancers, was associated with statistically significantly decreased disease-free survival (P =.006) and overall survival (P =.004) by univariate analysis. Similarly, increased MVD in metastases, but not in primary tumors, was statistically significantly associated with diminished overall survival in these patients (P =.02). In multivariate analysis, the number of positive axillary lymph nodes and the presence of vascular hot spots in axillary lymph node metastases predicted decreased disease-free survival (P =.0001 and.02, respectively) and overall survival (P =.0001 and.007, respectively). All P values were two-sided. CONCLUSION This pilot study suggests that assessing neovascularization in axillary lymph node metastases may provide clinically useful information regarding survival in patients with primary breast cancer.
Collapse
Affiliation(s)
- A J Guidi
- North Shore Medical Center, Salem, MA, USA
| | | | | | | | | | | | | |
Collapse
|
40
|
Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, Dewhirst M, Greenberg C. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000; 18:600-8. [PMID: 10653875 DOI: 10.1200/jco.2000.18.3.600] [Citation(s) in RCA: 113] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
PURPOSE To investigate the relationship between preoperative plasma D-dimer levels and extent of tumor involvement in operable breast cancer patients. PATIENTS AND METHODS A total of 140 preoperative plasma specimens were obtained from women scheduled to undergo diagnostic breast biopsies. Ninety-five patients in the initial group went on to undergo axillary lymph node dissection. Of the 140 patients from whom plasma samples were obtained, 102 were subsequently diagnosed with invasive breast carcinoma, nine were subsequently diagnosed with ductal carcinoma-in-situ, and 20 were subsequently diagnosed with benign breast disease. Plasma D-dimer levels were quantitated using a commercially available immunoassay kit (DIMERTEST; American Diagnostica, Greenwich, CT). The relationships between plasma D-dimer and other prognostic variables (tumor size, estrogen receptor, progesterone receptor, nuclear grade, histologic grade, lymphovascular invasion, and clinical stage grouping) were then examined using univariate and multivariate linear and logistic regression analyses. RESULTS Median plasma D-dimer levels were significantly higher in patients with invasive carcinoma than those patients with either benign breast disease or carcinoma-in-situ (P =.0001). A significant relationship existed between the presence of elevated D-dimer (> 100 ng/mL) and involved axillary lymph nodes (chi(2) test; P =.001). Elevated D-dimer levels predicted positive lymph node involvement in both univariate regression (P =.0035) and multivariate linear regression (P =.012) models. In addition, elevated D-dimer levels predicted the presence of lymphovascular invasion in univariate logistic regression (P =. 0025) and multivariate logistic regression analysis (P =.0053). Quantitative D-dimer levels were highly correlated with clinical stage grouping (analysis of variance test; P =.002). CONCLUSION Plasma D-dimer levels were markers of lymphovascular invasion, clinical stage, and lymph node involvement in operable breast cancer. This correlation suggests that detectable fibrin degradation, as measured by plasma D-dimer, is a clinically important marker for lymphovascular invasion and early tumor metastasis in operable breast cancer.
Collapse
MESH Headings
- Adult
- Aged
- Axilla
- Breast Neoplasms/blood
- Breast Neoplasms/pathology
- Breast Neoplasms/surgery
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Ductal, Breast/surgery
- Carcinoma, Intraductal, Noninfiltrating/blood
- Carcinoma, Intraductal, Noninfiltrating/pathology
- Carcinoma, Intraductal, Noninfiltrating/surgery
- Female
- Fibrin Fibrinogen Degradation Products/metabolism
- Humans
- Lymph Nodes/pathology
- Lymphatic Metastasis
- Middle Aged
- Pilot Projects
- Predictive Value of Tests
- Prospective Studies
- Regression Analysis
Collapse
Affiliation(s)
- K Blackwell
- Divisions of Medical and Radiation Oncology, Duke University Comprehensive Cancer Center, Durham, NC 27710, USA
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol 1999; 17:3064-74. [PMID: 10506601 DOI: 10.1200/jco.1999.17.10.3064] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
PURPOSE We performed a retrospective review to determine predictive and prognostic factors in patients with metastatic breast cancer who received induction therapy, and, if they responded to treatment, high-dose chemotherapy. PATIENTS AND METHODS Patients with metastatic breast cancer received induction therapy with doxorubicin, fluorouracil, and methotrexate (AFM). Partial responders then received immediate high-dose chemotherapy, whereas those who achieved complete remission were randomized to immediate or delayed high-dose chemotherapy with hematopoietic stem-cell support. We performed a retrospective review of data from these patients and used Cox proportional hazards regression models for analyses. RESULTS The overall response rate for the 425 patients enrolled was 74% (95% confidence interval, 70% to 78%). Multivariate analysis of data from all 425 patients revealed that positive estrogen receptor status (P =.0041), smaller metastatic foci (</= 2 v > 2 cm) (P =. 0165), a longer disease-free interval from initial diagnosis to diagnosis of metastases (</= 2 v > 2 years) (P =.0051), and prior treatment with tamoxifen (P =.0152) were good prognostic signs for overall survival. Patients who had received prior adjuvant therapy (P =.0001) and those who developed liver metastases (P =.0001) had decreased long-term survival. In the subgroup of responders to AFM induction, multivariate analysis showed that those with visceral metastases did less well (P =.0006), as did patients who had received prior adjuvant therapy (P =.0023). However, those who had received tamoxifen therapy in the adjuvant setting did better (P =. 0143). CONCLUSION The chance for long-term remission with induction therapy with AFM and high-dose chemotherapy is increased for hormone receptor positive-patients with nonvisceral metastases who have not received prior adjuvant chemotherapy and have long disease-free intervals.
Collapse
Affiliation(s)
- D A Rizzieri
- Duke University Medical Center Marrow and Stem Cell Transplantation Program, Durham, NC 27710, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Carter DL, Marks LB, Bean JM, Broadwater G, Hussein A, Vredenburgh JJ, Peters WP, Prosnitz LR. Impact of consolidation radiotherapy in patients with advanced breast cancer treated with high-dose chemotherapy and autologous bone marrow rescue. J Clin Oncol 1999; 17:887-93. [PMID: 10071280 DOI: 10.1200/jco.1999.17.3.887] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To examine the impact of consolidation radiotherapy (RT) after high-dose chemotherapy with autologous bone marrow rescue (HDC) in patients with advanced breast cancer. PATIENTS AND METHODS Between 1988 and 1994,425 patients with metastatic or recurrent breast cancer received doxorubicin, fluorouracil, and methotrexate (AFM) induction chemotherapy in a single-institution prospective trial. One hundred patients who achieved a complete response were randomized to receive HDC (cyclophosphamide, cisplatin, carmustine), with autologous bone marrow rescue immediately after AFM, or to observation, with HDC to be administered at next relapse. Seventy-four of the 100 became eligible for RT; 53 received consolidation RT (HDC RT+ and 21 did not (HDC RT-). The assignment of RT was not randomized. The RT+ and RT- groups were similar with regard to number of involved sites, the fraction of patients with only local-regional disease, age, and interval since initial diagnosis. Local control at previously involved sites and distant sites was assessed with extensive radiologic and clinical evaluations at the time of first failure or most recent follow-up. The impact of RT on failure patterns, event-free survival, and overall survival was evaluated. RESULTS Sites of first failure were located exclusively at previously involved sites in 28% of RT+ patients versus 62% of RT- patients (P < .01). Event-free survival at 4 years was 31% and 21% in the RT+ and RT-groups, respectively (P = .02). Overall survival at 4 years was 30% and 16% in the RT+ and RT- groups, respectively (P = .20). CONCLUSION Patients with advanced breast cancer who were treated with HDC without RT failed predominantly at the initial sites of disease. The addition of RT appeared to reduce the failure rate at initial disease sites and may improve event-free and overall survival. Our observations await verification in a trial in which assignment to RT is randomized.
Collapse
Affiliation(s)
- D L Carter
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Warmuth MA, Bowen G, Prosnitz LR, Chu L, Broadwater G, Peterson B, Leight G, Winer EP. Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer 1998; 83:1362-8. [PMID: 9762937 DOI: 10.1002/(sici)1097-0142(19981001)83:7<1362::aid-cncr13>3.0.co;2-2] [Citation(s) in RCA: 165] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND Axillary lymph node dissection is commonly performed as part of the primary management of breast carcinoma. Its value in patient management, however, has recently been questioned. Few studies exist that document long term complications. METHODS Four hundred thirty-two patients with Stage I or II breast carcinoma who were free of recurrence 2-5 years after surgery were identified. A cross-sectional survey was conducted to determine the prevalence of long term symptoms and complications as perceived by the patient, and patient and treatment factors that may have predicted complications were determined. Three hundred thirty of the 432 (76%) completed a mailed, self-administered questionnaire. In addition, the medical records of the 330 patients were reviewed. Patient and treatment factors were analyzed with logistic regression. RESULTS Numbness was reported by 35% of patients at the time of the survey. Pain was noted in 30%, arm swelling in 15%, and limitation of arm movement in 8%. Eight percent reported episodes of infection or inflammation at some point since the diagnosis of breast carcinoma. The majority of symptoms were mild and interfered minimally with daily activities. Younger age (P=0.001) was associated with more frequent reporting of pain. Numbness was more common in younger patients (P=0.004) as well as in those with a history of smoking (P=0.012). There was a positive association of limitation of arm motion with adjuvant tamoxifen therapy (P=0.016). Arm swelling was associated with both younger age (P=0.004) and greater body surface area (P=0.008). Radiation therapy was associated with a higher frequency of infection or inflammation in the arm and/or breast (P=0.001). CONCLUSIONS Mild symptoms, especially pain and numbness, are common 2-5 years after axillary lymph node dissection. The frequency of inflammation or infection in patients treated with radiation to the breast or chest wall after an axillary lymph node dissection may be greater than previously appreciated. Severe complications or symptoms that have a major impact on daily activities are uncommon. These findings should help health care providers and their patients with breast carcinoma weigh the pros and cons of axillary lymph node dissection.
Collapse
Affiliation(s)
- M A Warmuth
- Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Vredenburgh JJ, Silva O, Broadwater G, Berry D, DeSombre K, Tyer C, Petros WP, Peters WP, Bast RC. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant 1997; 3:91-7. [PMID: 9267669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We studied the incidence and significance of tumor cell contamination of the bone marrow or peripheral blood progenitor cells of patients who had high risk primary breast cancer involving 10 or more axillary lymph nodes and who received high dose cyclophosphamide, cisplatin, and carmustine with hematopoietic support as consolidation following standard dose adjuvant chemotherapy. The autologous hematopoietic cell products were evaluated in 85 eligible patients. Eighty-three samples were available from the time of bone marrow harvest, and peripheral blood progenitor cells were evaluated from 57 of the 65 patients who additionally received these products. The screening technique utilized a panel of four anti-breast cancer monoclonal antibodies and an immunohistochemical technique. Thirty (36%) of the 83 evaluable patients had tumor cell contamination of the bone marrow. Only 2 (4%) of the 57 patients had tumor cell contamination of the peripheral blood progenitor cells. Tumor cell contamination of the bone marrow was associated with shorter disease-free survival and overall survival. In addition, the higher the number of tumor cells identified, the shorter disease-free and overall survival. There was no relationship between the tumor cell contamination of the bone marrow and the site of relapse. The combination of the log of the number of tumor cells +1 and number of positive lymph nodes predicted both disease-free and overall survival. Tumor cell contamination of the bone marrow from the harvest is associated with shorter disease-free and overall survival for patients who were treated with standard dose chemotherapy followed by consolidation with high dose alkylating agents and hematopoietic support. It is unclear what role the contaminating tumor cells have in relapse, and they may just be a high-risk marker. A comparison with other prognostic factors and characteristics of the tumor may determine the significance of the tumor contamination of the bone marrow.
Collapse
Affiliation(s)
- J J Vredenburgh
- Duke University Bone Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina 27710, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|